+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Identification of paclitaxel analogs with activity in paclitaxel resistant human ovarian carcinoma cell lines



Identification of paclitaxel analogs with activity in paclitaxel resistant human ovarian carcinoma cell lines



International Journal of Oncology 7(Suppl. ): 1001




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 031788356

Download citation: RISBibTeXText


Related references

Characterization of two independent, exposure-time dependent paclitaxel-resistant human ovarian carcinoma cell lines. Human Cell 23(4): 156-163, 2010

Paclitaxel resistant human ovarian carcinoma cell lines without P-gp expression demonstrate an altered tubulin response to drug. Anticancer Research 15(5A): 1643, 1995

Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Research 28(2a): 1119-1127, 2008

Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clinical Cancer Research 2(10): 1725-1730, 1996

Tubulin from paclitaxel resistant human ovarian carcinoma cell lines demonstrates altered response to drug, in vivo and in vitro. Proceedings of the American Association for Cancer Research Annual Meeting 37: 320, 1996

Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. European Journal of Cancer 38(12): 1653-1660, 2002

Overexpression of alpha tubulins in paclitaxel treated and paclitaxel resistant human cancer cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 39: 190, 1998

Non-immunosuppressive cyclosporine derivative PSC 833 abolishes resistance of human multidrug-resistant ovarian carcinoma cells in vitro to paclitaxel and paclitaxel-induced radiosensitization. International Journal of Cancer 72(5): 916-917, 1997

Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Molecular Cancer Therapeutics 5(5): 1197-1208, 2006

Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells. International Journal of Oncology 41(5): 1837-1844, 2012

Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines. British Journal Of Cancer. 74(2): 224-228, 1996

Intermittent exposure to paclitaxel resulting high levels of non-MDR paclitaxel resistance in the human ovarian carcinoma cell line SKOV3. Proceedings of the American Association for Cancer Research Annual Meeting 37: 376, 1996

Proteomic analysis of human ovarian cancer paclitaxel-resistant cell lines. Zhong Nan Da Xue Xue Bao. Yi Xue Ban 35(4): 286-294, 2010

Phase II trial of PSC 833/paclitaxel in paclitaxel-resistant refractory ovarian carcinoma Renewed responses. Cancer Investigation 17(Suppl. 1): 41-42, 1999

The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67(9): 955-967, 2007